Otsuka Shinya, Inagaki Masaru, Nishie Manabu, Hamano Ryousuke, Tokunaga Naoyuki, Takahashi Kenji, Tsunemitsu Yousuke, Miyoshi Kazuya, Iwakawa Kazuhide, Takahashi Masahiko, Iwagak Hiromi
Department of Surgery, National Hospital Organization Fukuyama Medical Center.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2166-8.
A 25-year-old man with RS rectal cancer received a radical resection of the original tumor and lymph node dissection. Oral tegafur/uracil (UFT)/Leucovorin (LV) therapy has been used for adjuvant chemotherapy, as the pathological Stage was T3N1M0, Stage IIIa. After 10 months from operation, multiple liver metastases were recognized and not resectable. So a systemic chemotherapy by mFOLFOX6+bevacizumab was begun via CV port. After 5 courses of mFOLFOX6+bevacizumab, abdominal CT revealed liver metastases showed remarkable reduction in size. Hepatic resection of S6 segment was enforced, and the patient uneventfully discharged. Pathological findings of S6 segment revealed no residual cancer cells, indicating the histological effect of mFOLFOX6+bevacizumab was Grade 3. And no liver damage was recognized.
一名25岁的直肠癌患者接受了原发肿瘤根治性切除术及淋巴结清扫术。由于病理分期为T3N1M0（Ⅲa期），术后采用口服替加氟/尿嘧啶（UFT）/亚叶酸钙（LV）进行辅助化疗。术后10个月，发现多发肝转移且无法切除。因此，通过中心静脉导管开始采用mFOLFOX6+贝伐单抗进行全身化疗。经过5个疗程的mFOLFOX6+贝伐单抗治疗后，腹部CT显示肝转移灶大小显著缩小。遂进行了S6段肝切除术，患者术后顺利出院。S6段的病理检查结果显示无残留癌细胞，表明mFOLFOX6+贝伐单抗的组织学疗效为3级。且未发现肝损伤。
